

41. Mackenzie IR, Ansorge O, Strong M et al (2011) Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation. *Acta Neuropathol* 122:87–98
42. Groen EJ, van Es MA, van Vught PW et al (2010) FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands. *Arch Neurol* 67:224–230
43. Hara M, Minami M, Kamei S et al (2012) Lower motor neuron disease caused by a novel FUS/TLS gene frameshift mutation. *J Neurol* 259:2237–2239
44. Yamashita S, Mori A, Sakaguchi H et al (2012) Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. *J Neurol* 259:1039–1044
45. Munoz DG, Neumann M, Kusaka H et al (2009) FUS pathology in basophilic inclusion body disease. *Acta Neuropathol* 118:617–627
46. Neumann M, Rademakers R, Roeber S et al (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. *Brain* 132:2922–2931
47. Neumann M, Roeber S, Kretzschmar HA et al (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. *Acta Neuropathol* 118:605–616
48. Seelaar H, Klijnsma KY, de Koning I et al (2010) Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. *J Neurol* 257:747–753
49. Tateishi T, Hokenohara T, Yamasaki R et al (2010) Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. *Acta Neuropathol* 119:355–364
50. Suzuki N, Aoki M, Warita H et al (2010) FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. *J Hum Genet* 55:252–254
51. Deng HX, Zhai H, Bigio EH et al (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. *Ann Neurol* 67:739–748
52. Keller BA, Volkening K, Droppelmann CA et al (2012) Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. *Acta Neuropathol* 124:733–747
53. Huang EJ, Zhang J, Geser F et al (2010) Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. *Brain Pathol* 20:1069–1076
54. Huang C, Zhou H, Tong J et al (2011) FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. *PLoS Genet* 7:e1002011
55. Mitchell JC, McGoldrick P, Vance C et al (2013) Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. *Acta Neuropathol* 125:273–288
56. Hicks GG, Singh N, Nashabi A et al (2000) FUS deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability, and perinatal death. *Nat Genet* 24:175–179
57. Kuroda M, Sok J, Webb L et al (2000) Male sterility and enhanced radiation sensitivity in TLS (–/–) mice. *EMBO J* 19:453–462
58. Lagier-Tourenne C, Cleveland DW (2009) Rethinking ALS: the FUS about TDP-43. *Cell* 136:1001–1004
59. Ishigaki S, Masuda A, Fujioka Y et al (2012) Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. *Sci Rep* 2:529
60. Lagier-Tourenne C, Polymenidou M, Hutt KR et al (2012) Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. *Nat Neurosci* 15:1488–1497
61. Rogelj B, Easton LE, Bogu GK et al (2012) Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain. *Sci Rep* 2:603
62. Nakaya T, Alexiou P, Maragkakis M et al (2013) FUS regulates genes coding for RNA-binding proteins in neurons by binding to their highly conserved introns. *RNA* 19:498–509
63. Tsujii H, Iguchi Y, Furuya A et al (2013) Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. *EMBO Mol Med* 5:221–234
64. Yamazaki T, Chen S, Yu Y et al (2012) FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. *Cell Rep* 2:799–806
65. Chow CY, Zhang Y, Dowling JJ et al (2007) Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4 J. *Nature* 448:68–72
66. Chow CY, Landers JE, Bergren SK et al (2009) Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *Am J Hum Genet* 84:85–88
67. Volpicelli-Daley L, De Camilli P (2007) Phosphoinositides' link to neurodegeneration. *Nat Med* 13:784–786
68. Rutherford AC, Traer C, Wassmer T et al (2006) The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. *J Cell Sci* 119:3944–3957
69. Zhang Y, Zolov SN, Chow CY et al (2007) Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, results in neurodegeneration in mice. *Proc Natl Acad Sci USA* 104:17518–17523
70. Ferguson CJ, Lenk GM, Meisler MH (2010) PtdIns(3,5)P2 and autophagy in mouse models of neurodegeneration. *Autophagy* 6:170–171
71. Ferguson CJ, Lenk GM, Meisler MH (2009) Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. *Hum Mol Genet* 18:4868–4878
72. Maruyama H, Morino H, Ito H et al (2010) Mutations of optineurin in amyotrophic lateral sclerosis. *Nature* 465:223–226
73. Del Bo R, Tiloca C, Pensato V et al (2011) Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 82:1239–1243
74. Millicamps S, Boillee S, Chabrol E et al (2011) Screening of OPTN in French familial amyotrophic lateral sclerosis. *Neurobiol Aging* 32(557):e511–e553
75. Iida A, Hosono N, Sano M et al (2012) Optineurin mutations in Japanese amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 83:233–235
76. Zhu G, Wu CJ, Zhao Y et al (2007) Optineurin negatively regulates TNF $\alpha$ -induced NF- $\kappa$ B activation by competing with NEMO for ubiquitinated RIP. *Curr Biol* 17:1438–1443
77. Wild P, Farhan H, McEwan DG et al (2011) Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. *Science* 333:228–233
78. Sahlender DA, Roberts RC, Arden SD et al (2005) Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. *J Cell Biol* 169:285–295
79. Deng HX, Bigio EH, Zhai H et al (2011) Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. *Arch Neurol* 68:1057–1061
80. Hortobagyi T, Troakes C, Nishimura AL et al (2011) Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. *Acta Neuropathol* 121:519–527
81. Osawa T, Mizuno Y, Fujita Y et al (2011) Optineurin in neurodegenerative diseases. *Neuropathology* 31:569–574
82. Elden AC, Kim HJ, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* 466:1069–1075

83. Lee T, Li YR, Ingre C et al (2011) Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. *Hum Mol Genet* 20:1697–1700
84. Daoud H, Belzil V, Martins S et al (2011) Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. *Arch Neurol* 68:739–742
85. Gispert S, Kurz A, Waibel S et al (2012) The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. *Neurobiol Dis* 45:356–361
86. Van Damme P, Veldink JH, van Blitterswijk M et al (2011) Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. *Neurology* 76:2066–2072
87. Ross OA, Rutherford NJ, Baker M et al (2011) Ataxin-2 repeat-length variation and neurodegeneration. *Hum Mol Genet* 20:3207–3212
88. Farg MA, Soo KY, Warraich ST et al (2013) Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. *Hum Mol Genet* 22:717–728
89. Henneberger C, Papouin T, Oliet SH et al (2010) Long-term potentiation depends on release of D-serine from astrocytes. *Nature* 463:232–236
90. Sasabe J, Chiba T, Yamada M et al (2007) D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. *EMBO J* 26:4149–4159
91. Sasabe J, Miyoshi Y, Suzuki M et al (2012) D-amino acid oxidase controls motoneuron degeneration through D-serine. *Proc Natl Acad Sci USA* 109:627–632
92. Mitchell J, Paul P, Chen HJ et al (2010) Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. *Proc Natl Acad Sci USA* 107:7556–7561
93. Stevanin G, Santorelli FM, Azzedine H et al (2007) Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. *Nat Genet* 39:366–372
94. Orlicchio A, Babalini C, Borreca A et al (2010) SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. *Brain* 133:591–598
95. Watts GD, Wymer J, Kovach MJ et al (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet* 36:377–381
96. Johnson JO, Mandrioli J, Benatar M et al (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron* 68:857–864
97. Rohrer JD, Warren JD, Reiman D et al (2011) A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. *J Neurol* 258:1494–1496
98. Neumann M, Mackenzie IR, Cairns NJ et al (2007) TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. *J Neuropathol Exp Neurol* 66:152–157
99. Meyer H, Bug M, Bremer S (2012) Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. *Nat Cell Biol* 14:117–123
100. Ju JS, Fuentealba RA, Miller SE et al (2009) Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. *J Cell Biol* 187:875–888
101. Badadani M, Nalbandian A, Watts GD et al (2010) VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. *PLoS One* 5. doi: 10.1371/journal.pone.0013183
102. Custer SK, Neumann M, Lu H et al (2010) Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain, and bone. *Hum Mol Genet* 19:1741–1755
103. Yin HZ, Nalbandian A, Hsu CI et al (2012) Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. *Cell Death Dis* 3:e374
104. Deng HX, Chen W, Hong ST et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* 477:211–215
105. Williams KL, Warraich ST, Yang S et al (2012) UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. *Neurobiol Aging* 33:2527 e2523–2510
106. Rothenberg C, Srinivasan D, Mah L et al (2010) Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. *Hum Mol Genet* 19:3219–3232
107. Lee DY, Brown EJ (2012) Ubiquilins in the crosstalk among proteolytic pathways. *Biol Chem* 393:441–447
108. DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–256
109. Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72:257–268
110. Beck J, Poulter M, Hensman D et al (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. *Am J Hum Genet* 92:345–353
111. Cruts M, Gijselinck I, Van Langenhove T et al (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. *Trends Neurosci*
112. Smith BN, Newhouse S, Shatunov A et al (2013) The C9ORF72 expansion mutation is a common cause of ALS ± FTD in Europe and has a single founder. *Eur J Hum Genet* 21:102–108
113. Majounie E, Renton AE, Mok K et al (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. *Lancet Neurol* 11:323–330
114. Tsai CP, Soong BW, Tu PH et al (2012) A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. *Neurobiol Aging* 33:2232.e2211–2232.e2218
115. Ishiura H, Takahashi Y, Mitsui J et al (2012) C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. *Arch Neurol* 69:1154–1158
116. Ogaki K, Li Y, Atsuta N et al (2012) Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. *Neurobiol Aging* 33(2527):e2511–e2526
117. Konno T, Shiga A, Tsujino A et al (2013) Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. *J Neurol Neurosurg Psychiatry* 84:398–401
118. Jang JH, Kwon MJ, Choi WJ et al (2013) Analysis of the C9orf72 hexanucleotide repeat expansion in Korean patients with familial and sporadic amyotrophic lateral sclerosis. *Neurobiol Aging* 34(1311):e1317–e1319
119. Zou ZY, Li XG, Liu MS et al (2013) Screening for C9orf72 repeat expansions in Chinese amyotrophic lateral sclerosis patients. *Neurobiol Aging* 34(1710):e1715–e1716
120. Byrne S, Elamin M, Bede P et al (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. *Lancet Neurol* 11:232–240
121. Floris G, Borghero G, Cannas A et al (2012) Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype? *J Neurol* 259:1749–1751
122. Calvo A, Moglia C, Canosa A et al (2012) Amyotrophic lateral sclerosis/frontotemporal dementia with predominant

- manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the *c9orf72* gene. *J Neurol* 259:2723–2725
123. Al-Sarraj S, King A, Troakes C et al (2011) p62-positive, TDP-43-negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of *C9orf72*-linked FTL and MND/ALS. *Acta Neuropathol* 122:691–702
  124. Brettschneider J, Van Deerlin VM, Robinson JL et al (2012) Pattern of ubiquilin pathology in ALS and FTL indicates presence of *C9ORF72* hexanucleotide expansion. *Acta Neuropathol* 123:825–839
  125. Mori K, Weng SM, Arzberger T et al (2013) The *C9orf72* GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTL/ALS. *Science* 339:1335–1338
  126. Ash PE, Bieniek KF, Gendron TF et al (2013) Unconventional translation of *C9ORF72* GGGGCC expansion generates insoluble polypeptides specific to *c9FTD/ALS*. *Neuron* 77:639–646
  127. Levine TP, Daniels RD, Gatta AT et al (2013) The product of *C9orf72*, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. *Bioinformatics* 29:499–503
  128. Gijssels I, Van Langenhove T, van der Zee J et al (2012) A *C9orf72* promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. *Lancet Neurol* 11:54–65
  129. Wu CH, Fallini C, Ticozzi N et al (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. *Nature* 488:499–503
  130. Zou ZY, Sun Q, Liu MS et al (2013) Mutations in the profilin 1 gene are not common in amyotrophic lateral sclerosis of Chinese origin. *Neurobiol Aging* 34(1713):e1715–e1716
  131. van Blitterswijk M, Baker MC, Bieniek KF et al (2013) Profilin-1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia. *Amyotroph Lateral Scler Frontotemporal Degener*
  132. Tiloca C, Ticozzi N, Pensato V et al (2013) Screening of the *PFN1* gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. *Neurobiol Aging* 34:1517–1519
  133. Lattante S, Le Ber I, Camuzat A et al (2013) Mutations in the *PFN1* gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France. *Neurobiol Aging* 34(1709):e1701–e1702
  134. Ingre C, Landers JE, Rizik N et al (2013) A novel phosphorylation site mutation in profilin 1 revealed in a large screen of US, Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia cohorts. *Neurobiol Aging* 34(1708):e1701–e1706
  135. Dillen L, Van Langenhove T, Engelborghs S et al (2013) Explorative genetic study of *UBQLN2* and *PFN1* in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. *Neurobiol Aging* 34(1711):e1711–e1715
  136. Daoud H, Dobrzaniecka S, Camu W et al (2013) Mutation analysis of *PFN1* in familial amyotrophic lateral sclerosis patients. *Neurobiol Aging* 34(1311):e1311–e1312
  137. Chen Y, Zheng ZZ, Huang R et al (2013) *PFN1* mutations are rare in Han Chinese populations with amyotrophic lateral sclerosis. *Neurobiol Aging* 34(1922):e1921–e1925
  138. Yang S, Fifita JA, Williams KL et al (2013) Mutation analysis and immunopathological studies of *PFN1* in familial and sporadic amyotrophic lateral sclerosis. *Neurobiol Aging* 34:2235–2237
  139. Mockrin SC, Korn ED (1980) *Acanthamoeba* profilin interacts with G-actin to increase the rate of exchange of actin-bound adenosine 5'-triphosphate. *Biochemistry* 19:5359–5362
  140. Wills Z, Marr L, Zinn K et al (1999) Profilin and the Abl tyrosine kinase are required for motor axon outgrowth in the *Drosophila* embryo. *Neuron* 22:291–299
  141. Al-Saif A, Al-Mohanna F, Bohlega S (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. *Ann Neurol* 70:913–919
  142. Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. *Cell* 131:596–610
  143. Mavlyutov TA, Epstein ML, Andersen KA et al (2010) The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. *Neuroscience* 167:247–255
  144. Katsuno M, Tanaka F, Sobue G (2012) Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. *J Neurol Neurosurg Psychiatry* 83:329–335
  145. Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 3:CD001447
  146. Mackenzie IR, Bigio EH, Ince PG et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with *SOD1* mutations. *Ann Neurol* 61:427–434
  147. Tan CF, Eguchi H, Tagawa A et al (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without *SOD1* gene mutation. *Acta Neuropathol* 113:535–542
  148. Egawa N, Kitaoka S, Tsukita K et al (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. *Sci Transl Med* 4:145ra104
  149. Fecto F, Yan J, Vemula SP et al (2011) *SQSTM1* mutations in familial and sporadic amyotrophic lateral sclerosis. *Arch Neurol* 68:1440–1446
  150. Sasaki S (2011) Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol* 70:349–359
  151. Wang IF, Guo BS, Liu YC et al (2012) Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. *Proc Natl Acad Sci USA* 109:15024–15029
  152. Anderson P, Kedersha N (2008) Stress granules: the Tao of RNA triage. *Trends Biochem Sci* 33:141–150
  153. Colombrita C, Zennaro E, Fallini C et al (2009) TDP-43 is recruited to stress granules in conditions of oxidative insult. *J Neurochem* 111:1051–1061
  154. Andersson MK, Stahlberg A, Arvidsson Y et al (2008) The multifunctional *FUS*, *EWS* and *TAF15* proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. *BMC Cell Biol* 9:37
  155. Nonhoff U, Ralsler M, Welzel F et al (2007) Ataxin-2 interacts with the DEAD/H-box RNA helicase *DDX6* and interferes with P-bodies and stress granules. *Mol Biol Cell* 18:1385–1396
  156. Nishimoto Y, Ito D, Yagi T et al (2010) Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. *J Biol Chem* 285:608–619
  157. Bosco DA, Lemay N, Ko HK et al (2010) Mutant *FUS* proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. *Hum Mol Genet* 19:4160–4175
  158. Dormann D, Rodde R, Edbauer D et al (2010) ALS-associated fused in sarcoma (*FUS*) mutations disrupt Transportin-mediated nuclear import. *EMBO J* 29:2841–2857
  159. Liu-Yesucevitz L, Bilgutay A, Zhang YJ et al (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. *PLoS One* 5:e13250

160. Nonaka T, Masuda-Suzukake M, Arai T et al (2013) Prion-like properties of pathological TDP-43 aggregates from diseased brains. *Cell Rep* 4:124–134
161. Couthouis J, Hart MP, Shorter J et al (2011) A yeast functional screen predicts new candidate ALS disease genes. *Proc Natl Acad Sci USA* 108:20881–20890
162. Couthouis J, Hart MP, Erion R et al (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. *Hum Mol Genet* 21:2899–2911
163. Kim HJ, Kim NC, Wang YD et al (2013) Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* 495:467–473

# RNP2 of RNA Recognition Motif 1 Plays a Central Role in the Aberrant Modification of TDP-43

Shinnosuke Takagi<sup>1</sup>, Yohei Iguchi<sup>1</sup>, Masahisa Katsuno<sup>1\*</sup>, Shinsuke Ishigaki<sup>1</sup>, Kensuke Ikenaka<sup>1</sup>, Yusuke Fujioka<sup>1</sup>, Daiyu Honda<sup>1</sup>, Jun-ichi Niwa<sup>2</sup>, Fumiaki Tanaka<sup>3</sup>, Hirohisa Watanabe<sup>1</sup>, Hiroaki Adachi<sup>1</sup>, Gen Sobue<sup>1\*</sup>

**1** Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan, **2** Stroke Center, Aichi Medical University, Aichi, Japan, **3** Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

## Abstract

Phosphorylated and truncated TAR DNA-binding protein-43 (TDP-43) is a major component of ubiquitinated cytoplasmic inclusions in neuronal and glial cells of two TDP-43 proteinopathies, amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Modifications of TDP-43 are thus considered to play an important role in the pathogenesis of TDP-43 proteinopathies. However, both the initial cause of these abnormal modifications and the TDP-43 region responsible for its aggregation remain uncertain. Here we report that the 32 kDa C-terminal fragment of TDP-43, which lacks the RNP2 motif of RNA binding motif 1 (RRM1), formed aggregates in cultured cells, and that similar phenotypes were obtained when the RNP2 motif was either deleted from or mutated in full-length TDP-43. These aggregations were ubiquitinated, phosphorylated and truncated, and sequestered the 25 kDa C-terminal TDP-43 fragment seen in the neurons of TDP-43 proteinopathy patients. In addition, incubation with RNase decreased the solubility of TDP-43 in cell lysates. These findings suggest that the RNP2 motif of RRM1 plays a substantial role in pathological TDP-43 modifications and that it is possible that disruption of RNA binding may underlie the process of TDP-43 aggregation.

**Citation:** Takagi S, Iguchi Y, Katsuno M, Ishigaki S, Ikenaka K, et al. (2013) RNP2 of RNA Recognition Motif 1 Plays a Central Role in the Aberrant Modification of TDP-43. PLoS ONE 8(6): e66966. doi:10.1371/journal.pone.0066966

**Editor:** Emanuele Buratti, International Centre for Genetic Engineering and Biotechnology, Italy

**Received:** February 7, 2013; **Accepted:** May 15, 2013; **Published:** June 28, 2013

**Copyright:** © 2013 Takagi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by Center-of-Excellence (COE) grant; Ministry of Education, Culture, Sports, Science and Technology/Japan Society for the Promotion of Science KAKENHI Grant Numbers 21229011, 21689024, 22110005, and 23390230; Strategic Research Program for Brain Sciences, MEXT, Japan; Health Labour Sciences Research Grants, MHLW, Japan; and Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Agency (JST). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: sobueg@med.nagoya-u.ac.jp (GS); ka2no@med.nagoya-u.ac.jp (MK)

## Introduction

Amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal lobar degeneration (FTLD) with ubiquitin-positive but tau-negative inclusions have been considered to be a single disease spectrum of TAR DNA-binding protein 43 (TDP-43) proteinopathy since 2006, when this protein was reported to be a major component of ubiquitin-positive inclusions in the affected neuronal and glial cells of both ALS and FTLD [1–3]. The identification of missense mutations of *TARDBP*, the gene encoding TDP-43, in familial and sporadic ALS and/or FTLD patients further confirmed the importance of this molecule in the pathogenesis of TDP-43 proteinopathies [4–7].

Although TDP-43 normally localizes to the nucleus, it is distributed from nucleus to cytoplasm or neurite and forms aggregates that mainly consist of C-terminal fragments (CTFs) in the affected neurons of TDP-43 proteinopathy patients. In addition, aberrantly aggregated TDP-43 is hyperphosphorylated at multiple C-terminal sites [8]. The fact that most TDP-43 proteinopathy cases are sporadic suggests that exogenous factors induce the post-translational modifications of TDP-43 that are seen in the disease.

Although it does not fully recapitulate the pathological features of TDP-43 proteinopathies, artificial axonal damage induces


transient cytoplasmic distribution of TDP-43 in mouse motor neurons [9,10], and several stress conditions, including oxidative stress and suppression of the ubiquitin-proteasome system, cause aberrant modifications of TDP-43 in cultured cell lines or primary neurons [11–15]. In addition, a motor neuron-specific disruption of proteasomes results in the cytosolic distribution of TDP-43 in a mouse model [16]. Finally, the repeat expansion of GGGGCC in C9orf72, as well as mutations in UBQLN2, VCP, PGRN, or OPTN, lead to neurodegeneration with TDP-43-positive neuronal inclusions [17–22].

These findings provide us with a clue for elucidating the mechanism of these modifications. Nevertheless, both the initial cause of these abnormal modifications and the region of TDP-43 responsible for its aggregation remain unknown. Here we report that RNP2 in RNA binding motif 1 (RRM1) plays a substantial role in the pathological TDP-43 modifications that are seen in TDP-43 proteinopathies.

## Materials and Methods

### Cell Culture and Treatment

Mouse NSC34 motor neuron-like cells (a kind gift of N.R. Cashman, University of British Columbia, Vancouver, Canada) [23] and human embryonic kidney 293 (HEK293) cells were



**Figure 1. Intracellular localizations of TDP-43 lacking the NLS and of CTFs of TDP-43.** (A) Structures of wild-type (Wt), NLS-disrupted mutant (dNLS) and CTFs (TDP35, TDP32 and TDP25). (B) Immunoblots of the cytosol and nuclear fractions from HEK293 cells expressing Wt, dNLS, TDP35, TDP32, or TDP25.




doi:10.1371/journal.pone.0066966.g001

cultured in a humidified atmosphere of 95% air/5% CO<sub>2</sub> in a 37°C incubator in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). In both NSC34 and HEK293 cells, the transfections of the intended plasmids were performed using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Before performing subsequent experiments, the cells were incubated for 48 h after transfection.

#### DNA Constructs

Human wild-type TDP-43 (WT-TDP-43) (accession number NM 007375) cDNA was amplified by PCR from human spinal cord cDNA as previously described [11]. The PCR product was cloned into the pENTR/D-TOPO vector (Invitrogen). For the TDP-43 truncated fragments, amplified PCR products (for primers see Table S1) from the WT-TDP-43 vector were cloned into the pENTR/D-TOPO vector. For delta RNP2 TDP-43 ( $\Delta$ RNP2), mutated RNP2 TDP-43 (mtRNP2), mutated RNP1

TDP-43 (mRNP1), delta RRM1 TDP-43 ( $\Delta$ RRM1), and delta nuclear localization signal (NLS) TDP-43 (dNLS) vectors, primers containing mutant substitutions (Table S2) were used to mutagenize WT-TDP-43 (KOD-Plus-Mutagenesis kit; Toyobo). The entry vectors of each mutant TDP-43 vector were transferred into either a pcDNA6.2/N-EmGFP-DEST or pcDNA3.1/nV5-DEST vector using the Gateway LR Clonase II enzyme mix (Invitrogen). The sequences of all constructs were verified using the CEQ 8000 genetic analysis system (Beckman Coulter). The collection of autopsied human tissue and its use for this study were approved by the Ethics Committee of Nagoya University Graduate School of Medicine, and written informed consent was obtained from the patients' next-of-kin. The experimental procedure involving the human subject was conducted in conformance with the principles expressed in the Declaration of Helsinki.



**Figure 2. Ubiquitination of TDP-43 CTFs.** (A) Immunocytochemistry of NSC34 cells expressing Wt, dNLS, TDP35, or TDP32. Cells were stained with anti-ubiquitin antibody (green), anti-V5 antibody (red), and DAPI (blue). Scale bar = 5  $\mu$ m. (B) Percentage of cells with ubiquitin-positive aggregates. Error bars indicate SEM (n=3). The percentage of TDP32-expressing cells containing ubiquitin-positive aggregates was significantly higher than that of cells expressing TDP35 ( $p<0.05$ ). (C) Immunoprecipitations with anti-ubiquitin antibody. The immunoreactivity of V5 was only detected in the TDP32 lane (arrow head). Asterisk indicates non-specific signal. (D) Immunoprecipitations with anti-V5 antibody. The ubiquitin-positive smear band was increased in the lane of TDP32 compared with that of TDP35. Asterisks indicate a heavy or light chain of IgG. doi:10.1371/journal.pone.0066966.g002

### Immunoblot Analysis

We used NE-PER Nuclear Cytoplasmic Reagents (Thermo Fisher Scientific) for the analysis of the cytoplasmic/nuclear ratio. For analysis of protein solubility, cells cultured in 10-cm plates were lysed in 1 ml RIPA buffer (Thermo Fisher Scientific). Lysates were sonicated and centrifuged at 100,000  $g$  for 15 min. To prevent carryover, the pellets were washed with RIPA buffer, followed by sonication and centrifugation. RIPA-insoluble pellets were lysed in 100  $\mu$ l urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.5), sonicated, and centrifuged at 100,000  $g$  for 15 min.

After the denaturation, 5  $\mu$ l of each sample was separated by SDS-PAGE (5%–20% gradient gel) and the proteins were then transferred to Hybond-P membranes (Amersham Pharmacia Biotech). The membranes were blocked with 5% skimmed milk in Tris-buffered saline containing 0.05% Tween-20 and incubated with the intended primary antibodies. The primary antibodies used were as follows: anti-TDP-43 rabbit polyclonal antibody (1:1000; ProteinTech); anti-pTDP-43 (phospho Ser409/410) rabbit polyclonal antibody (1:1000; Cosmo Bio); anti-ubiquitin mouse monoclonal antibody (MBL); anti-histone H1 mouse monoclonal antibody (1:500; Millipore); anti-GAPDH mouse monoclonal antibody (1:2000; Temecula); anti-GFP mouse monoclonal antibody (1:2000; MBL); and anti-V5 mouse monoclonal antibody (1:5000; Invitrogen). For the anti-ubiquitin antibody, the membranes were fixed with 0.05% glutaraldehyde/0.1M  $\text{KH}_2\text{PO}_4$  and blocked with 4% BSA. Secondary antibody probing and detection were performed using ECL Plus detection reagents (GE Healthcare). Chemiluminescence signals were digitized (LAS-3000 Imaging System; Fujifilm) and band intensities were quantified using Multi Gauge software (version 3.0; Fujifilm).

### Immunocytochemistry

NSC34 cells were fixed in 4% paraformaldehyde, incubated in PBS containing 0.3% Triton X-100 for 5 min, blocked with Image-iT FX signal enhancer (Invitrogen), and incubated overnight at 4°C with anti-TDP-43 rabbit polyclonal antibody (1:1000; ProteinTech), anti-pTDP-43 (phospho Ser409/410) rabbit polyclonal antibody (1:500; Cosmo Bio), anti-TIAR mouse monoclonal antibody (1:500; BD Transduction Laboratories, Milan, Italy), anti-ubiquitin mouse monoclonal antibody (1:100; MBL), anti-V5 rabbit polyclonal antibody (1:1000; Bethyl) or anti-V5 mouse monoclonal antibody (Invitrogen). After washing, samples were incubated with Alexa-488-conjugated goat anti-mouse IgG and Alexa-555-conjugated goat anti-rabbit IgG (both at 1:1000; Invitrogen) for 60 min, mounted with Prolong Gold antifade reagent with DAPI (Invitrogen), and then imaged with a confocal microscope (LSM710; Zeiss).

For the counting of inclusion-bearing cells, we randomly selected 100 transfected cells from three separate experiments. The colocalization coefficient, which reflects the fraction of green pixels that are also positive for red pixels, was calculated using the Zeiss LSM software. We calculated the colocalization coefficient by randomly selected 10 fields from three separate experiments. To obtain images for calculating the colocalization coefficient, the

settings of the confocal microscopy and the threshold of positive/negative fluorescence was fixed within each experiment.

### Immunoprecipitation

Transfected HEK293 cells were washed with PBS and lysed in immunoprecipitation buffer (Thermo Fisher Scientific). After sonication on ice, the samples were agitated for 30 min at 4°C. The samples were centrifuged and supernatants were incubated with magnetic beads: anti-V5 magnetic beads (MBL), anti-GFP magnetic beads (MBL), and anti-ubiquitin magnetic beads (MBL). Samples were rotated overnight at 4°C. Immunoprecipitates were separated by SDS-PAGE (5%–20% gradient gel). Western blotting was performed using anti-V5-HRP antibody (MBL) and anti-GFP-HRP antibody (MBL).

### Ribonucleoprotein Immunoprecipitation

Ribonucleoprotein (RNP) immunoprecipitation was performed using a RIP assay kit (MBL), according to the manufacturer's instructions. RNA concentrations were measured with a Nano-drop (Thermo Fisher Scientific). Electrophoresis of precipitated RNA was performed with a Bioanalyzer (Agilent Technologies) according to the manufacturer's instructions. For analysis of neurofilament light chain (hNFL) mRNA 3'UTR content, RNA obtained from immunoprecipitates was reverse transcribed into first-strand cDNA using SuperScript II reverse transcriptase (Invitrogen) and a PCR was performed with the following primers: ACCAACCAGTTGAGTTCCAGAT (forward) and GAATGATTCACATTGCCGTAGA (reverse).


### Effect of RNase on TDP-43 Solubility

For analysis of protein solubility with or without RNase, HEK293 cells cultured in 10-cm plates were lysed in 1 ml of Tris-saline (TS) buffer (50 mM Tris-HCl buffer, pH 7.5, 0.15 M NaCl, 5 mM EDTA, protein phosphatase inhibitors, and a protease inhibitor cocktail). Lysates were sonicated and then divided into two samples. RNase A (10  $\mu$ g/ml) was added to one of the samples. Samples incubated for 0 and 15 h at 4°C were centrifuged at 100,000  $g$  for 15 min. To prevent carryover, the pellets were washed with TS buffer, followed by sonication and centrifugation. TS-insoluble pellets were lysed in 1 ml of Triton X-100 (TX) buffer (TS buffer containing 1% Triton X-100), sonicated, and centrifuged at 100,000  $g$  for 15 min. The pellets were washed with TX buffer, followed by sonication and centrifugation. TX-insoluble pellets were lysed in 500  $\mu$ l of Sarkosyl (Sar) buffer (TS buffer containing 1% Sarkosyl), sonicated and centrifuged at 100,000  $g$  for 15 min. Sar-insoluble pellets were lysed in 100  $\mu$ l of urea buffer.


### Statistical Analyses

Statistical analyses were performed using GraphPad Prism software (GraphPad software inc.). Biochemical data were statistically analyzed using a Student's *t*-test or one-factor factorial ANOVA followed by Tukey post hoc tests. A *p* value of 0.05 or less was considered to be statistically significant.






**Figure 3. Phosphorylation and insolubilization of TDP32.** (A) Immunocytochemistry of NSC34 cells expressing Wt, dNLS, TDP35, or TDP32. Cells were stained with anti-pTDP-43 antibody (green), anti-V5 antibody (red), and DAPI (blue). Scale bar = 5  $\mu$ m. (B) Percentage of cells with pTDP-43-positive aggregates. Error bars indicate SEM (n=3). The percentage of TDP32-expressing cells containing pTDP-43-positive aggregates was significantly higher than that of TDP35 ( $p < 0.01$ ). (C and D) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing TDP35 and TDP32. The amount of insoluble TDP32 was higher than that of TDP35 (C). TDP32 in the RIPA-insoluble fraction was detected with anti-pTDP-43 antibody (D).  
doi:10.1371/journal.pone.0066966.g003



**Figure 4. Disruption of the RNP2 motif leads to ubiquitin-positive aggregates of TDP-43.** (A) Structures of Wt, ΔRNP2, and mtRNP2. (B) Immunocytochemistry of NSC34 cells expressing Wt, ΔRNP2, or mtRNP2. Cells were stained with anti-ubiquitin antibody (green), anti-V5 antibody (red), and DAPI (blue). Scale bar = 5 μm. (C) Percentage of cells with ubiquitin-positive aggregates. Error bars indicate SEM (n = 3). The percentage of mtRNP2 and ΔRNP2-expressing cells containing ubiquitin-positive aggregates was significantly higher than that of Wt-expressing cells (*p* < 0.01 and *p* < 0.001, respectively). (D) Immunoprecipitations with anti-ubiquitin antibody. The V5-positive smear band was evident in the mtRNP2 lane. (E) Immunoprecipitations with anti-V5 antibody. The ubiquitin-positive smear band was increased in the mtRNP2 lane compared with that of the Wt. doi:10.1371/journal.pone.0066966.g004



**Figure 5. Phosphorylation and insolubilization of RNP2-disrupted TDP-43.** (A) Immunocytochemistry of NSC34 cells expressing  $\Delta$ RNP2 or mtRNP2. Cells were stained with anti-pTDP-43 antibody (green), anti-V5 antibody (red), and DAPI (blue). Scale bar = 5  $\mu$ m. (B) Percentage of cells with pTDP-43-positive aggregates. Error bars indicate SEM ( $n=3$ ). The percentage of mtRNP2 and  $\Delta$ RNP2-expressing cells containing pTDP-43-positive aggregates was significantly higher than that of Wt-expressing cells ( $p<0.01$  and  $p<0.01$ , respectively). (C and D) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing Wt or mtRNP2. The amount of insoluble mtRNP2 was higher than that of Wt (C). mtRNP2 in the RIPA-insoluble fraction was detected with anti-pTDP-43 antibody (D). doi:10.1371/journal.pone.0066966.g005


## Results

### Intracellular Localization of CTFs of TDP-43 in NSC34 Cells

To identify the region of TDP-43 that is responsible for the pathological modification of this protein, we created various TDP-43 mutants and investigated their intracellular localizations. In particular, given that the CTFs of TDP-43 form aggregates in the cytoplasm of affected neurons, we focused on the mutant TDP-43 in which the NLS is disrupted (dNLS) and on TDP-43 CTFs:

35 kDa (TDP35), 32 kDa (TDP32), and 25 kDa (TDP25) fragments (Fig. 1A). We examined TDP32, which does not contain RNP2 motif (aa 106–111), to access the effect of RNA-binding on the pathological modification, since RNP2 motif is indispensable for RNA-binding of RRM1 [24]. Each form of TDP-43 was transfected into NSC34 cells for immunocytochemical analysis and into HEK293 cells for the analysis of their localization using fractionated immunoblots.

Although wild-type TDP-43 showed a nuclear-dominant distribution, the dNLS mutant localized to the cytosol more



**Figure 6. Biological features of the 25 kDa CTF of TDP-43.** (A) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing TDP35, TDP32, or TDP25. (B) Immunocytochemistry of cells expressing TDP25. Cells were stained with anti-ubiquitin (green), anti-V5 (red), and DAPI (blue). TDP25 was diffusely distributed and did not form aggregates. Scale bar=5  $\mu$ m. (C and D) Immunoblots of RIPA-soluble and -insoluble fractions from cells expressing Wt, mtRNP2, TDP35, or TDP32. Small fragments (~26 kDa) of TDP-43 were detected in the lanes of mtRNP2 and TDP32 (C) and were immunoreactive to anti-pTDP-43 antibody (D). doi:10.1371/journal.pone.0066966.g006

preferentially than wild-type TDP-43 (Fig. 1B). The CTFs of TDP-43, all of which lack the NLS, also showed a cytosolic localization. In particular, the short CTFs, TDP32 and TDP25, had a strong propensity to distribute in the cytosol. We also found that the total soluble protein levels of TDP32 and TDP25 were less than that of TDP35, suggesting that these two CTFs may be insoluble or rapidly degraded.


#### Ubiquitination of TDP-43 CTFs

The relatively low steady-state levels of TDP32 and TDP25 prompted us to explore the possibility that these CTFs form aggregates. Given that the expression levels of TDP25 are substantially lower than other forms of TDP-43, we first focused on dNLS, TDP35, and TDP32. In immunocytochemical analysis using anti-ubiquitin and -V5 antibodies, wild-type TDP-43 chiefly localized to the nucleus, but a substantial amount of dNLS and TDP35 distributed to the cytosol (Fig. 2A). TDP32 also showed a

cytosolic localization but formed aggregates that were stained with anti-ubiquitin antibody (Fig. 2A, B).

In contrast, ubiquitin-positive aggregates were virtually undetectable in the cells expressing TDP35 (Fig. 2B). Since TDP-43 is reported to form RNA-containing structures like stress granules, we examined the relationship between TDP-43 CTFs and T-cell-restricted intracellular antigen 1-related (TIAR) protein, a marker of stress granules. Although TDP35 occasionally colocalized with TIAR, the inclusions of TDP32 were distinct from anti-TIAR-stained RNA granules (Fig. S1).

To quantitatively analyze the relationship between ubiquitin and TDP-43 CTFs, we calculated the colocalization coefficient of ubiquitin and V5 immunofluorescence. We found that the colocalization coefficient of ubiquitin and V5 was significantly higher in TDP32-expressing cells than in those expressing TDP35 ( $p < 0.001$ ; Fig. S2). We also confirmed using immunoprecipitation the differential ubiquitination of TDP35 and TDP32. Anti-




**Figure 7. The 25 kDa CTF binds to TDP-43 lacking the RNP2 motif.** (A) Structures of CTFs (wild-type, TDP25, and TDP14). (B) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing GFP-Wt or mtRNP2. (C) Immunocytochemistry of NSC34 cells expressing GFP-mtRNP2 together with V5-TDP25. Cells were stained with anti-V5 (red) and DAPI (blue). Scale bar = 5  $\mu$ m. (D and E) Immunoprecipitations with anti-GFP (D) or anti-V5 (E) antibody from cells expressing GFP-TDP25 and V5-mtRNP2. (F and G) Immunoprecipitations with anti-GFP (F) or anti-V5 (G) antibody from cells expressing GFP-TDP14 and V5-mtRNP2.  
doi:10.1371/journal.pone.0066966.g007

ubiquitin immunoprecipitates were only detected in the cells expressing TDP32, although the steady-state levels of TDP32 were far lower than those of TDP35 (Fig. 2C). Immunoblotting of anti-V5 immunoprecipitates also showed that the ubiquitin-positive smear was denser in the cells bearing TDP32 than in those expressing TDP35 (Fig. 2D). Together, these results suggest that TDP32, but not TDP35, forms ubiquitin-positive aggregates.

**Insolubilization and Phosphorylation of the 32 kDa CTF of TDP-43**

Like ubiquitination, insolubilization and phosphorylation are characteristics of TDP-43 proteinopathies. Therefore, we investigated TDP-43 CTF solubility and phosphorylation, finding that although the cytosolic aggregates of TDP32 were well stained with anti-phosphorylated TDP-43 (pTDP-43) antibody, the other forms



**Figure 8. A decrease in cellular RNA increases the insolubility of TDP-43.** (A) Electrophoresis of total RNA immunoprecipitated with wild-type TDP-43 or mRNP2. (B) Results of RNA concentration analysis. The amount of RNA that binds to mRNP2 was significantly decreased in comparison with wild-type TDP-43 ( $p < 0.001$ ). (C) Immunoblots of the immunoprecipitated protein with anti-V5 antibody or control IgG. (D) Reverse transcription-PCR (RT-PCR) of hNFL from immunoprecipitated RNA. The 3'UTR of hNFL was clearly detected by RT-PCR from RNA that binds to wild-type TDP-43. (E) Immunoblots of sequential extractions from cell lysates with or without RNase. The incubations with RNase induced insolubilization of TDP-43.

doi:10.1371/journal.pone.0066966.g008

showed no detectable pTDP-43-containing aggregates (Fig. 3A). The quantitative analysis also confirmed that the number of pTDP-43-positive aggregates was significantly higher in the cells expressing TDP32 than in those transfected with the TDP35 vector ( $p < 0.01$ ; Fig. 3B). The colocalization coefficient of TDP-43 CTFs and phosphorylated TDP-43 was also significantly higher in the cells expressing TDP32 than in those with TDP35 ( $p < 0.001$ ; Fig. S3). In the immunoblots performed using RIPA lysis buffer, the amount of insoluble TDP32 was higher than that of TDP35, whereas most of the TDP35 was solubilized by this buffer (Fig. 3C). TDP32 in the RIPA-insoluble fraction was also detected with an anti-pTDP-43 antibody (Fig. 3D).

#### Disruption of the RNP2 Motif in TDP-43 Leads to Ubiquitin-positive Aggregate Formation

The phenotype of TDP32 was distinctly different from that of TDP35, although both of which lack the NLS, span amino acids 85–414 and 112–414, respectively (Fig. 1A). Although these two CTFs, and share a common structure with regard to the RRM2 and glycine-rich domains. The critical difference between these CTFs is the RNP2 (aa 106–111), the RNA binding motif at its N-

terminal portion, which was included in TDP35 but not in TDP32. The contrast between TDP35 and TDP32 regarding modifications suggests that RNP2 motif is responsible for the induction of critical changes such as ubiquitination, phosphorylation, and insolubilization.

To investigate the role of the RNP2 motif in the modification of TDP-43, we created two defective mutants,  $\Delta$ RNP2 and mRNP2 (Fig. 4A). While  $\Delta$ RNP2 has no RNP2 motif, mRNP2 contains the mutated RNP2 in which leucine residues were changed to aspartic acid, as previously reported [24]. The NSC34 cells overexpressing these mutants bear ubiquitin-positive inclusions in both the nucleus and cytosol (Fig. 4B, C). In immunocytochemical analyses, the inclusions of  $\Delta$ RNP2 and mRNP2 were distinct from RNA granules labeled with the anti-TIAR antibody (Fig. S4). The colocalization coefficient of mRNP2 and ubiquitin was significantly higher than that of wild-type TDP-43 and ubiquitin ( $p < 0.001$ ; Fig. S5).

Immunoprecipitation analyses showed that mRNP2 inclusions were strongly ubiquitinated in comparison with those of wild-type TDP-43 (Fig. 4D, E). Inclusions of  $\Delta$ RNP2 and mRNP2 were also immunoreactive to the anti-pTDP-43 antibody (Fig. 5A, B). The

colocalization coefficient of mtRNP2 and pTDP-43 was significantly higher than that of wild-type TDP-43 and pTDP-43 ( $p < 0.05$ ; Fig. S6). The amount of mtRNP2 in the RIPA-insoluble fraction was higher than that of wild-type TDP-43 (Fig. 5C). Additionally, mtRNP2 was more phosphorylated than wild-type TDP-43 (Fig. 5D). These results further demonstrate the features of TDP32, supporting the view that RNP2 has a protective role for the pathological modification of TDP-43. Since V5 tag possibly has a certain effect on these modifications, we also assessed the biological properties of non-tagged mtRNP2 TDP-43. The results showed that mtRNP2 without a tag became also insoluble and hyperphosphorylated (Fig. S7A). In addition, we investigated TDP-43 with disrupted RNP1 motif (mtRNP1) in RRM1, which is also responsible for RNA binding of TDP-43. The mtRNP1 was insoluble and phosphorylated compared with wild-type TDP-43 (Fig. S7B).

### Biological Features of the 25 kDa CTF of TDP-43

Small CTFs of 18–26 kDa accumulate in the cytosol of affected neurons of TDP-43 proteinopathies [8,25]. However, in the present cellular study, the 25 kDa CTF of TDP-43 (TDP25) was soluble (Fig. 6A) and scarcely formed ubiquitin-positive aggregates (Fig. 6B). These findings indicate that TDP25 is not insoluble when simply overexpressed in cultured cells. Given that TDP25 contains the complete RRM2 and C-terminal domains of TDP-43, our results suggest that these domains of TDP-43 do not by themselves play an essential role in aggregation. To confirm this hypothesis, we assessed the phenotype of C-terminal domain-lacking mtRNP2 mutants: mtRNP2 (1–273), which has RRM1 and RRM2; mtRNP2 (1–185), which contains RRM1 but not RRM2; and TDP-43 (1–105), which lacks both RRM1 and RRM2. The results showed that both mtRNP2 (1–273) and mtRNP2 (1–185) formed aggregates, whereas TDP-43 (1–105) lacking both RRMs diffusely located in the nucleus without aggregation (Fig. S8A, B). In addition,  $\Delta$ RRM1 of TDP-43 did not apparently form aggregates (Fig. S8A, B). Although  $\Delta$ RRM1 showed a punctate nuclear localization, it was not insoluble or phosphorylated in the immunoblots (Fig. S8C). Taken together, the disrupted RNP2 in conjunction with the remaining RRM1 is likely to be necessary for the aggregation of TDP-43.

Next we investigated whether the 18–26 kDa TDP-43 fragments are included in the aggregates of the CTFs we created. Following prolonged exposure of the immunoblots of TDP-43 mutants, we found that 25 kDa and shorter fragments were detected in the insoluble fraction of TDP32 and mtRNP2, but not TDP35, using pan-TDP-43 antibody (Fig. 6C). These fragments were also detected using the anti-pTDP-43 antibody that reacts with phosphorylated serines at the C-terminus of TDP-43 (Ser409/410) (Fig. 6D). Therefore, our findings indicate that the 25 kDa CTF of TDP-43 is included in the aggregation of TDP-43 mutants lacking the RNP2, though TDP25 does not by itself form aggregates. Since GFP-tagged TDP25 has been reported to form aggregates [26–28], we assessed the solubility of GFP-TDP-43 fragments. GFP-TDP35, TDP32, and TDP25 were all intensely insoluble (Fig. S9A). However, the features of non-tagged TDP-43 fragments were similar to those of V5-TDP-43 fragments: TDP32 was substantially insoluble, whereas TDP35 and TDP25 were less insoluble (Fig. S9B). These findings suggest that V5 tag appears to be suitable to assess the solubility of TDP-43 fragments.

### The 25 kDa CTFs Bind to TDP-43 Lacking the RNP2 Motif

Since 25 kDa and shorter CTFs were detected in the insoluble fraction of mtRNP2, we assumed that mtRNP2 binds to, and thereby sequesters, the 25 kDa CTF. To test this hypothesis,

experiments using the 25 kDa and 14 kDa CTFs of TDP-43 were performed (Fig. 7A). We co-transfected V5-tagged TDP25 and GFP-tagged TDP-43 in HEK293 cells and fractionated the whole cell lysates to obtain RIPA-soluble and -insoluble fractions. The amount of V5-TDP25 in the insoluble fraction was remarkably increased by GFP-mtRNP2, although we hardly detected the band of V5-TDP25 in the insoluble fraction of the cells expressing wild-type TDP-43 (Fig. 7B). Immunocytochemical confocal microscope analysis also demonstrated that V5-TDP25 was colocalized with the aggregates of GFP-mtRNP2 in the cytosol (Fig. 7C).

Next we performed immunoprecipitation to examine the binding of small CTFs to mtRNP2. The results showed that TDP25 binds to V5-mtRNP2, but not to the V5-mtRNP2 (1–273) that lacks the C-terminal domain of TDP-43 (Fig. 7D, E). Since TDP25 includes the RRM2 (aa 191–262), a shorter CTF, TDP14, was also used to determine whether the RRM2 is necessary for the binding to mtRNP2. TDP14, which spans amino acids 274–414, lacks RRM2, but contains the C-terminal region where most ALS-related mutations are located. The results showed that GFP-TDP14 efficiently binds to V5-mtRNP2 as well as GFP-TDP25 (Fig. 7F, G). In addition, we confirmed that mtRNP2, as well as TDP35 and TDP32, showed no interaction with IgG/beads (Fig. S10). These results suggest that small CTFs, seen in the neurons of ALS and FTLD patients bind to the C-terminal domain of mtRNP2 and are sequestered into the cytosolic aggregates of mtRNP2, and that the RRM2 is not required for this interaction. Although our results suggest that wild-type TDP-43 also interacts with the CTFs, this might result from the effect of the GFP tag given that GFP-TDP25 tends to be insoluble as shown in Fig. S7A.

### A Decrease in Cellular RNA Enhances the Insolubility of TDP-43

The RNP2 motif of RRM1 is important for its RNA binding ability [24]. To confirm that mtRNP2 lacks the ability to bind to RNA, we performed RNP immunoprecipitation. The results showed that the amount of RNA that binds to TDP-43 is decreased by the disruption of RNP2, although the efficiency of precipitation was similar between wild-type TDP-43 and mtRNP2 (Fig. 8A–C). We also tested whether mtRNP2 binds to the 3'UTR of the mRNA of human neurofilament light chain (NFL), a known target of TDP-43 [29,30], using RNP immunoprecipitation followed by PCR. The results showed that wild-type TDP-43, but not mtRNP2, binds to the 3'UTR of NFL mRNA, confirming that mtRNP2 loses its ability to bind to the target RNA of TDP-43 (Fig. 8D).

Based on the observation that the disruption of the RNP2 motif increases the aggregation of TDP-43, we hypothesized that the decreased binding to RNA leads to the formation of insoluble aggregates of TDP-43. Therefore, we investigated the effects of RNase on the properties of the endogenous TDP-43. To increase the detection sensitivity of insolubilized TDP-43, we used a mild buffer and four-step fractionation. The results demonstrated that the amount of urea-insoluble endogenous TDP-43 was increased from that of the start sample (0 h) by a 16-h incubation with RNase (Fig. 8E).

### Discussion

The ubiquitin-positive, phosphorylated inclusion of TDP-43 in neuronal cytoplasm is a pathological hallmark of TDP-43 proteinopathy. Since this inclusion contains 18–26 kDa CTFs of TDP-43 that do not have the RRM1 [8,25], the phenotype of the TDP-43 CTFs have been intensively investigated. Previous studies showed that the 35 kDa TDP-43 CTF is sequestered into stress

granules in cultured cells [31,32], whereas the 25 kDa CTF phenotype findings have been controversial [25–28,31,33–35]: several reports did demonstrate that 25 kDa of TDP-43 forms cytosolic aggregates but most were tagged with fluorescent proteins. Therefore, a small tag, V5, was used to assess the cellular distribution of TDP-43 in our experiments.

We first focused on the physical features of two types of TDP-43 CTFs, TDP35 and TDP32. The cells expressing TDP32 only exhibited ubiquitin-positive and phosphorylated aggregations. In addition, the immunoblots also showed that TDP32, but not TDP35, was insoluble and phosphorylated, suggesting that the RNP2 motif in the RRM1 is responsible for the process of TDP-43 aggregation. Although the cells expressing TDP35 occasionally appeared to form cytoplasmic aggregates, those were the components of stress granules and were neither insoluble nor ubiquitinated. On the other hand, the cells expressing TDP25 did not form aggregates in our experimental conditions, although the TDP25 did not contain the RNP2 motif. This discrepancy might be explained by our observation that the disrupted RNP2 motif and the remaining RRM1, but not RRM2, are both required for the aggregations of TDP-43. In addition, the finding that  $\Delta$ RRM1 TDP-43 does not form aggregates also supports this hypothesis.

Since the RNP2 motif in the RRM1 is responsible for the ability of TDP-43 to bind RNAs with specific sequences [24], a disruption of RNA binding could cause the aberrant aggregation of TDP-43. The cells with either  $\Delta$ RNP2 or mtRNP2 TDP-43 formed aggregates and underwent both phosphorylation and ubiquitination. Disruption of RNP1, another RNA binding motif, also insolubilizes TDP-43. In addition, incubation with RNase caused insolubilization of endogenous TDP-43. These data further confirmed that RNA binding is important for the process of TDP-43 aggregation. Since the interaction of negatively charged RNA is responsible for the conformation of RNA-binding proteins, RNA may exert a chaperoning effect on its bound proteins [36]. Therefore, when the interaction of TDP-43 with RNA is disrupted, a consequent conformational change could cause TDP-43 to aggregate, and affect the function of NLS in this protein. Previous studies that demonstrated reduced levels of RNA in the motor neurons of ALS patients may support our hypothesis [37].

We have discussed the fact that the CTFs did not, except for TDP32, aggregate in normal conditions, whereas full-length TDP-43 could aggregate when RNA binding is disrupted. However, a question is raised as the major components of aggregated TDP-43 in TDP-43 proteinopathy patients are CTFs, such as TDP25. Although TDP25 did not by itself aggregate in our system, the cells expressing mtRNP2 or TDP32 contained ~25 kDa phosphorylated TDP-43 in their insoluble fractions. In addition, in the cells co-expressing mtRNP2 and TDP25, TDP25 formed aggregates and colocalized with mtRNP2, suggesting that mtRNP2 sequesters TDP25 in the aggregations.

On the other hand, mtRNP2 (1–273), which lacks the C-terminal domain, did not have the ability to sequester TDP25. The C-terminal domain of TDP-43, in which most of the disease mutations are located, contains a glutamine/asparagine-rich (Q/N-rich) domain; also referred to as the prion-like domain, it is involved in the self-assembly of misfolded CTFs and the sequestration of TDP-43 into polyglutamine aggregates [38–40]. Therefore, it is possible that TDP-43 in which RNA binding is disrupted forms the initial aggregation core, and further sequesters TDP-43 CTF into the aggregation through interactions with the C-terminal domain.

In summary, we demonstrated that the RNP2 motif in RRM1 plays a substantial role in pathological TDP-43 modifications and

that disruption of RNA binding may underlie the process of TDP-43 aggregation.

## Supporting Information

**Figure S1 Immunocytochemistry of NSC34 cells expressing TDP35 or TDP32.** Cells were stained with anti-V5 (red) and anti-TIAR (green) antibodies. The aggregates with TDP35, but not TDP32, colocalized with TIAR. Scale bar = 5  $\mu$ m. (TIF)

**Figure S2 The colocalization coefficient of the ubiquitin and V5 signals.** Cells were stained with anti-V5 (green) and anti-ubiquitin (red) antibodies. Colocalization with ubiquitin was significantly higher in the cells expressing TDP32 than in those bearing TDP35 ( $p < 0.001$ ). Scale bar = 5  $\mu$ m. Error bars indicate SEM (n = 3). (TIF)

**Figure S3 The colocalization coefficient of the pTDP-43 and V5 signals.** Cells were stained with anti-V5 (green) and anti-pTDP-43 (red) antibodies. Colocalization with pTDP-43 was significantly higher in the cells bearing TDP32 than in those expressing TDP35 ( $p < 0.001$ ). Scale bar = 5  $\mu$ m. Error bars indicate SEM (n = 3). (TIF)

**Figure S4 Immunocytochemistry of NSC34 cells expressing  $\Delta$ RNP2 or mtRNP2.** Cells were stained with anti-V5 (red) and anti-TIAR (green) antibodies. TIAR did not colocalize with the aggregates of  $\Delta$ RNP2 or mtRNP2. Scale bar = 5  $\mu$ m. (TIF)

**Figure S5 The colocalization coefficient of the ubiquitin and V5 signals.** Cells were stained with anti-V5 (green) and anti-ubiquitin (red) antibodies. Colocalization with ubiquitin was significantly higher in the cells expressing mtRNP2 than in those bearing wild-type TDP-43 ( $p < 0.001$ ). Scale bar = 5  $\mu$ m. Error bars indicate SEM (n = 3). (TIF)

**Figure S6 The colocalization coefficient of the pTDP-43 and V5 signals.** Cells were stained with anti-V5 (green) and anti-pTDP-43 (red) antibodies. Colocalization with pTDP-43 was significantly higher in the cells expressing mtRNP2 than in those with wild-type of TDP-43 ( $p < 0.05$ ). Scale bar = 5  $\mu$ m. Error bars indicate SEM (n = 3). (TIF)

**Figure S7 Biological features of non-tagged mtRNP2 and V5-tagged mtRNP1.** (A) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing non-tagged wild-type and mtRNP2 TDP-43. (B) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing V5-tagged wild-type and mtRNP1 TDP-43. (TIF)

**Figure S8 Intracellular localizations of N-terminal fragments of TDP-43 with mutated RNP2 and TDP-43 lacking RRM1.** (A) Structures of mtRNP2, mtRNP2 (1–273), mtRNP2 (1–185), TDP (1–105), and  $\Delta$ RRM1 TDP-43. (B) Images of NSC34 cells expressing V5-mtRNP2 (1–273), mtRNP2 (1–185), TDP (1–105), and  $\Delta$ RRM1 TDP-43. The cells bearing mtRNP2 (1–273) and mtRNP2 (1–185), but not mtRNP2 (1–105) or  $\Delta$ RRM1, formed aggregates. Scale bar = 10  $\mu$ m. (C) Immunoblots



of RIPA-soluble and -insoluble fractions from HEK293 cells expressing wild-type and  $\Delta$ RRM1. (TIF)

**Figure S9 Effect of tag on TDP-43 insolubilization.** (A) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing GFP-tagged wild-type and CTFs of TDP-43. (B) Immunoblots of RIPA-soluble and -insoluble fractions from HEK293 cells expressing non-tagged wild-type and CTFs of TDP-43. (TIF)

**Figure S10 Lack of interaction between TDP-43 mutants and IgG/beads.** Immunoprecipitations with mouse IgG from cells expressing wild-type and mutations of TDP-43.

## References

- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* 351: 602–611.
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314: 130–133.
- Chen-Plotkin AS, Lee VM, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. *Nat Rev Neurol* 6: 211–220.
- Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, et al. (2008) TDP-43 A315T mutation in familial motor neuron disease. *Ann Neurol* 63: 535–538.
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet* 40: 572–574.
- Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* 319: 1668–1672.
- Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, et al. (2008) TDP-43 mutation in familial amyotrophic lateral sclerosis. *Ann Neurol* 63: 538–542.
- Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, et al. (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Ann Neurol* 64: 60–70.
- Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, et al. (2009) Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. *Brain Res* 1249: 202–211.
- Sato T, Takeuchi S, Saito A, Ding W, Bamba H, et al. (2009) Axonal ligation induces transient redistribution of TDP-43 in brainstem motor neurons. *Neuroscience* 164: 1565–1578.
- Iguchi Y, Katsuno M, Takagi S, Ishigaki S, Niwa J, et al. (2012) Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. *Neurobiol Dis* 45: 862–870.
- Ayala V, Granado-Serrano AB, Cacabelos D, Naudi A, Ilieva EV, et al. (2011) Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. *Acta Neuropathol* 122: 259–270.
- Caragounis A, Price KA, Soon CP, Filiz G, Masters CL, et al. (2010) Zinc induces depletion and aggregation of endogenous TDP-43. *Free Radic Biol Med* 48: 1152–1161.
- Wang X, Fan H, Ying Z, Li B, Wang H, et al. (2010) Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. *Neurosci Lett* 469: 112–116.
- van Eersel J, Ke YD, Gladbach A, Bi M, Gotz J, et al. (2011) Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. *PLoS One* 6: e22850.
- Tashiro Y, Urushitani M, Imoue H, Koike M, Uchiyama Y, et al. (2012) Motor neuron-specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. *J Biol Chem* 287: 42984–42994.
- Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72: 257–268.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72: 245–256.
- Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, et al. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* 477: 211–215.
- Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, et al. (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron* 68: 857–864.
- Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, et al. (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. *Brain* 129: 3081–3090.
- Maruyama H, Morino H, Ito H, Izumi Y, Kato H, et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. *Nature* 465: 223–226.
- Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, et al. (1992) Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. *Dev Dyn* 194: 209–221.
- Buratti E, Baralle FE (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of C17orf90 exon 9. *J Biol Chem* 276: 36337–36343.
- Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, et al. (2009) Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. *J Neurochem* 110: 1082–1094.
- Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M (2009) Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. *Hum Mol Genet* 18: 3353–3364.
- Zhang YJ, Xu YF, Cook C, Gendron TF, Roettesges P, et al. (2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. *Proc Natl Acad Sci U S A* 106: 7607–7612.
- Yang C, Tan W, Whitte C, Qiu L, Cao L, et al. (2010) The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. *PLoS One* 5: e15878.
- Strong MJ, Volkening K, Hammond R, Yang W, Strong W, et al. (2007) TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. *Mol Cell Neurosci* 35: 320–327.
- Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ (2009) Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). *Brain Res* 1305: 168–182.
- Nishimoto Y, Ito D, Yagi T, Nihei Y, Tsunoda Y, et al. (2010) Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. *J Biol Chem* 285: 608–619.
- Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, et al. (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. *PLoS One* 5: e13250.
- Pesiridis GS, Tripathy K, Tanik S, Trojanowski JQ, Lee VM (2011) A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. *J Biol Chem* 286: 18845–18855.
- Voigt A, Herholz D, Fiesel FC, Kaur K, Muller D, et al. (2010) TDP-43-mediated neuron loss in vivo requires RNA-binding activity. *PLoS One* 5: e12247.
- Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, et al. (2009) Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. *J Biol Chem* 284: 8516–8524.
- Choi SI, Han KS, Kim CW, Ryu KS, Kim BH, et al. (2008) Protein solubility and folding enhancement by interaction with RNA. *PLoS One* 3: e2677.
- Mann DMA, Yates P (1974) Motor neurone disease: the nature of the pathogenic mechanism. *J Neurol Neurosurg Psychiatry* 37: 1036–1046.
- Cushman M, Johnson BS, King OD, Güler AD, Shorter J (2010) Prion-like disorders: blurring the divide between transmissibility and infectivity. *J Cell Sci* 123: 1191–1201.
- Wang JF, Chang HY, Hou SC, Liou GG, Way TD, et al. (2012) The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. *Nat Commun* 3: 766.
- Fuentealba RA, Udán M, Bell S, Wegorzewska I, Shao J, et al. (2010) Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. *J Biol Chem* 285: 26304–26314.

journal homepage: [www.elsevier.com/locate/febsopenbio](http://www.elsevier.com/locate/febsopenbio)

# The ALS/FTLD-related RNA-binding proteins TDP-43 and FUS have common downstream RNA targets in cortical neurons<sup>☆</sup>

Daiyu Honda<sup>a</sup>, Shinsuke Ishigaki<sup>a,\*</sup>, Yohei Iguchi<sup>a</sup>, Yusuke Fujioka<sup>a</sup>, Tsuyoshi Udagawa<sup>a</sup>, Akio Masuda<sup>b</sup>, Kinji Ohno<sup>b</sup>, Masahisa Katsuno<sup>a</sup>, Gen Sobue<sup>a,\*</sup>

<sup>a</sup>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

<sup>b</sup>Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan

## ARTICLE INFO

### Article history:

Received 13 August 2013

Received in revised form 11 November 2013

Accepted 11 November 2013

### Keywords:

ALS

FTLD

TDP-43

FUS

Transcriptome

## ABSTRACT

**TDP-43 and FUS are linked to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), and loss of function of either protein contributes to these neurodegenerative conditions. To elucidate the TDP-43- and FUS-regulated pathophysiological RNA metabolism cascades, we assessed the differential gene expression and alternative splicing profiles related to regulation by either TDP-43 or FUS in primary cortical neurons. These profiles overlapped by >25% with respect to gene expression and >9% with respect to alternative splicing. The shared downstream RNA targets of TDP-43 and FUS may form a common pathway in the neurodegenerative processes of ALS/FTLD.**

© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies. All rights reserved.

## 1. Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the death of motor neurons in the spinal cord, brainstem, and motor cortex [1]. Frontotemporal lobar degeneration (FTLD) is a dementia syndrome characterized by progressive changes in behavior, personality, and/or language resulting from the gradual deterioration of the frontal and temporal lobes [2,3]. Transactive response (TAR) DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS) have been genetically and pathologically linked to ALS and FTLD; however, the underlying mechanisms by which TDP-43 and FUS induce ALS and FTLD pathologies are unknown [2,3].

<sup>☆</sup> This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abbreviations:** ALS, amyotrophic lateral sclerosis; Cugbp1, CUG triplet repeat, RNA-binding protein 1; DAVID, Database for Annotation, Visualization and Integrated Discovery; FTLD, frontotemporal lobar degeneration; FUS, fused in sarcoma; GFAP, glial fibrillary acidic protein; GO, Gene Ontology; hnRNAPs, heterogeneous ribonucleoproteins; LTP, long-term potentiation; RIN, RNA integrity numbers; RMA, robust multichip average; RRM, RNA recognition motifs; SBMA, spinal and bulbar muscular atrophy; shCont, shRNA/control; shCugbp1, shRNA/Cugbp1; shFUS, shRNA/FUS; shTDP, shRNA/TDP-43; TDP-43, transactive response (TAR) DNA-binding protein 43; TGF, transforming growth factor.

\* Corresponding authors. Address: Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan. Tel.: +81 52 744 2391; fax: +81 52 744 2785. Tel.: +81 52 744 2385; fax: +81 52 744 2785.

E-mail addresses: [ishigaki-ns@umin.net](mailto:ishigaki-ns@umin.net) (S. Ishigaki) [sobueg@med.nagoya-u.ac.jp](mailto:sobueg@med.nagoya-u.ac.jp) (G. Sobue).

TDP-43 was identified as a major component of cytoplasmic neuronal inclusions in sporadic ALS and FTLD patients [4,5], and missense mutations in *TARDDBP*, the gene encoding TDP-43, are a known cause of familial ALS and FTLD [6–8]. Familial cases of ALS and FTLD involving TDP-43 mutations and sporadic cases of these diseases exhibit highly similar clinical and pathological characteristics [9], suggesting that TDP-43 plays an important role in the pathogenesis of sporadic ALS and FTLD. Similarly, FUS is also a causative gene for familial ALS and FTLD; in these diseases, redistribution to the cytoplasm and the formation of cytoplasmic aggregates occur for both the TDP-43 and FUS proteins [10,11]. TDP-43 and FUS also share many common pathophysiological characteristics. In particular, these proteins are structurally similar heterogeneous ribonucleoproteins (hnRNPs), as both TDP-43 and FUS are RNA-binding proteins with RNA recognition motifs (RRMs); they are typically predominantly found in the nucleus; their pathological forms are located mainly in the cytosol; and they are involved in transcription, alternative splicing, translation, and RNA transport [12–14].

Although it remains unclear whether a loss of function or gain of toxicity of TDP-43 or FUS is a major cause of ALS/FTLD, the loss of these RNA-binding proteins in the nucleus is a plausible trigger of neurodegeneration. This hypothesis has been supported by several lines of evidence, including the fact that TDP-43 or FUS nuclear staining is lost in the nuclei of neurons in both human ALS/FTLD tissue [15,16] and TDP-43 overexpressing mice [17,18]. In addition, animal models involving the loss of either TDP-43 or FUS mimic the pathology of ALS/FTLD [19–22]. Recently, analyses of TDP-43 using fly models revealed

that the up- and down-regulation of TDP-43 produced highly similar transcriptome alterations [23]. Cross-rescue analysis in *Drosophila* demonstrated that FUS acted together with and downstream of TDP-43 in a common genetic pathway [21]. Thus, it is intriguing to compare the transcriptome profiles from neurons with silenced TDP-43 or FUS. This experiment could clarify the common molecular mechanisms of ALS/FTLD that are associated with TDP-43 and FUS.

Recently, we investigated the transcriptome profiles of FUS regulation in different cell lineages of the central nervous system and determined that FUS regulates both gene expression and alternative splicing events in a cell-specific manner that is associated with ALS/FTLD [24]. In the current study, we investigated the transcriptome profiles of TDP-43-silenced primary cortical neurons and compared these profiles with the transcriptome profiles of FUS-silenced neurons. The gene expression and alternative splicing event profiles related to regulation by TDP-43 and by FUS were rather similar, suggesting that TDP-43 and FUS may regulate common downstream RNA targets and molecular cascades that could potentially be associated with the pathomechanisms of ALS/FTLD.

## 2. Methods

### 2.1. Lentivirus

We designed two different shRNAs against mouse *Tardbp* (*Tdp-43*), *Fus*, and a control shRNA. The targeted sequences were 5'-CGATGAACCCATTGAAATA-3' for shRNA/TDP-43-1 (shTDP1); 5'-GAGTGGAGGTTATGGTCAA-3' for shRNA/TDP-43-2 (shTDP2); 5'-GCAACAAGCTACGGACAA-3' for shRNA/FUS1 (shFUS1); 5'-GAGTGGAGGTTATGGTCAA-3' for shRNA/FUS2 (shFUS2); 5'-GGCTAAAGTGCAGCTCAA-3' for shRNA/Cugbp1 (shCugbp1); and 5'-AAGCAAAGATGTCTGAATA-3' for shRNA/control (shCont). The shRNAs were cloned into a lentiviral shRNA vector (pLenti-RNAi-X2 puro DEST, w16-1, which was a kind gift from Dr. Eric Campeau at Resverlogix Corp.). Lentivirus was prepared in accordance with the protocols detailed by Campeau et al. [25].

### 2.2. Primary cortical neuron culture and the depletion of TDP-43 and FUS

Primary cortical neurons were obtained from the fetal brains of C57BL/6 mouse embryos on embryonic day 15 (E15). The detailed procedure for acquiring these neurons was described in previously published reports [26]. On day 5, neurons were infected with  $2 \times 10^{10}$  copies/well ( $1.5 \times 10^7$  copies/ $\mu$ l) of lentivirus expressing shRNA against mouse *Tdp-43* (shTDP1 or shTDP2), mouse *Cugbp1* (CUG triplet repeat, RNA-binding protein 1) (shCugbp1), or scrambled control (shCont). The virus-containing media was removed at 4 h after infection. The neurons were then cultured for 6 additional days and harvested on day 11 for RNA extraction and cDNA synthesis. Each knockdown experiment was performed in triplicate for each microarray analysis. Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health and with the approval of the Nagoya University Animal Experiment Committee (Nagoya, Japan). The experiments on FUS-silenced primary cortical neurons were performed in the manner described above and have been detailed in a previously published report [26].

For immunohistochemical analyses, we used an anti- $\beta$ -tubulin antibody (TU20, Santa Cruz, Santa Cruz, CA), an anti-glial fibrillary acidic protein (GFAP) antibody (EB4, Enzo Life Sciences, Plymouth Meeting, PA), and 4',6-diamidino-2-phenylindole (DAPI) staining.

For immunoblot analyses, cells were lysed in TNE buffer containing protease inhibitors for 15 min on ice. The lysates were then cleared by

centrifuging the cells at 13,000g for 15 min at 4 °C. Lysates were normalized for total protein (10  $\mu$ g per lane), separated using a 4–20% linear gradient SDS-PAGE and electroblotted. For immunoblot, we used anti-FUS antibodies (A300–293A, Bethyl Laboratories, Montgomery, TX), anti-TDP-43 antibody (Proteintech, Chicago, IL), and anti-actin antibody (Sigma, St. Louis, MO).

### 2.3. Microarray analysis

Total RNA was extracted from primary cortical neurons using the RNeasy Mini Kit (Qiagen, Hilden, Germany). We confirmed that the RNA integrity numbers (RIN) for the extracted samples were all greater than 7.0. We synthesized and labeled cDNA fragments from 100 ng of total RNA using the GeneChip WT cDNA Synthesis Kit (Ambion, Austin, TX). Hybridization and signal acquisition for the GeneChip Mouse Exon 1.0 ST Array (Affymetrix, Santa Clara, CA) were performed according to the manufacturer's instructions. Each array experiment was performed in triplicate. The robust multichip average (RMA) and iterative probe logarithmic intensity error (iPLIER) methods were employed to normalize exon-level and gene-level signal intensities, respectively, using Expression Console 1.1.2 (Affymetrix). We utilized the gene annotation provided by Ensembl version e!61, which is based on the National Center for Biotechnology Information (NCBI) Build 37.1/mm9 of the mouse genome assembly. All microarray data were registered in the Gene Expression Omnibus with accession numbers of GSE36153 (shFUS) and GSE46148 (shTDP-43 and shCugbp1).

Using Student's *t*-test, we compared the gene-level signal intensities from three controls treated with shCont with the gene-level signal intensities of three samples treated with either shTDP1 or shTDP2. We also analyzed alternative splicing profiles by filtering the exon-level signal intensities, using a *t*-test with a threshold of *p*-value  $\leq 0.1$ . Gene expression and alternative splicing profiles related to FUS regulation in primary cortical neurons were also obtained by comparing gene-level and exon-level signal intensities from three controls treated with shCont with the corresponding signal intensities from three samples treated with either shFUS1 or shFUS2, as previously described [26]. As a control for the RNA-binding protein-silencing model, we analyzed the gene-level and exon-level signal intensities of three samples treated with either shCugbp1 or shCont.


### 2.4. RT-PCR for alternative splicing analyses

Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). The extracted RNA was then treated with DNase I (Qiagen). cDNA was synthesized from 1  $\mu$ g of total RNA using oligo(dT) primers (Promega, Madison, WI). Primers for each candidate exon were designed using the Primer3 software program (<http://frodo.wi.mit.edu/primer3/input.htm>). The primer sequences are provided in Supplementary Table 1. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed using Ex Taq (Takara Bio Inc., Otsu, Japan), with the following amplification conditions: 25–30 cycles of 98 °C for 10 s, 60 °C for 30 s, and 72 °C for 1 min. The PCR products were electrophoresed on a 15% acrylamide gel and stained with ethidium bromide. The intensity of each band was measured using the Multi Gauge software program (Fujifilm, Tokyo, Japan).


### 2.5. Real-time qPCR for gene expression analysis

The RNeasy Mini Kit (Qiagen) was used to isolate total RNA from cells; 1  $\mu$ g of total RNA was then reverse transcribed, using oligo-dT primers. This transcription utilized the CFX96 system (BioRad, Hercules, CA) and thermocycler conditions of 95 °C for 3 min followed by 40 cycles of 95 °C for 10 s and 55 °C for 30 s.

A



B



**Fig. 1.** Comparisons of the gene expression and exon splicing profiles of TDP-43-silenced primary cortical neurons and FUS-silenced primary cortical neurons. (A) Gene expression and alternative splicing profiles of TDP-43-silenced primary cortical neurons- and FUS-silenced primary cortical neurons were compared. Venn diagrams indicate the overlaps in the genes (top) and exons (bottom) with expression levels that were uniquely or concordantly regulated by TDP-43 and/or FUS ( $t$ -test,  $p < 0.05$ ; fold change  $\leq 0.67$  or  $\geq 1.5$ ). (B) The fold changes in overlapping genes filtered by  $t$ -tests (with a threshold of  $p < 0.1$ ) were plotted for TDP-43-silenced primary cortical neurons and FUS-silenced primary cortical neurons. Scatter plots of the fold changes in gene expression levels (left) and alternative splicing events (right) for shTDP-43 and shFUS. The  $R^2$  value was calculated for genes and exons with  $t$ -test  $p$ -values  $< 0.1$ .